New Nigerian Minister of Health is Early Supporter of Guided Therapeutics’ LuViva® Advanced Cervical Scan use in Africa

First Study of LuViva in Africa by Minister Issac Adewole, M.D.
detected 100% of disease

ABUJA, Nigeria–(BUSINESS WIRE)–Professor Issac Adewole, M.D., the newly appointed Minister of Health
for Nigeria, is an early proponent of the benefits of using the LuViva®
Advanced Cervical Scan from Guided Therapeutics, Inc. (OTCQB: GTHP) and
conducted the first clinical trial of the product in Africa.

When presenting study results to the Society of Gynecology and
Obstetrics of Nigeria in November 2014, Minister Adewole said, “These
results are encouraging and demonstrate the value of LuViva as a means
to detect cervical disease, even in the absence of a positive human
papillomavirus result, while also providing a means to reduce
unnecessary additional testing. In addition to the accuracy displayed in
the study, LuViva is painless and results are immediate – important
attributes for the patient and healthcare provider, particularly in
rural communities.”

“Congratulations to Minister Adewole on his appointment to this very
important leadership position,” said Gene Cartwright, CEO and President
of Guided Therapeutics, Inc. “We look forward to working with Minister
Adewole and the Ministry to advance the state of women’s health in
Nigeria and all of Africa.”

Before being named Minister of Health, Professor Adewole served as the
Vice Chancellor of the University of Ibadan and former President of the
African Organisation for Research and Training in Cancer. Prior to his
appointment as the 11th substantive Vice Chancellor of the University,
he served as Provost, College of Medicine, University of Ibadan, the
largest and oldest Medical school in Nigeria. His research interest is
in the area of Human papillomavirus, HIV and Gynecologic oncology, a
specialized field of medicine that focuses on cancers of the female
reproductive system, including ovarian cancer, uterine cancer, vaginal
cancer, cervical cancer, and vulvar cancer. Read
more about Minister Adewole here.

A 100-patient study led by Professor Adewole conducted at University
Teaching Hospital in Ibadan, Nigeria, concluded that LuViva was able to
detect 100% of serious pre-cancer (Cervical intraepithelial neoplasia
2+, CIN2+) while identifying, and thereby eliminating, up to 40% of
false positive results, or women who were actually disease free, from
further testing. These results are consistent with other published
studies conducted in North America. Three of the CIN2+ cases correctly
identified by LuViva tested negative for HPV at the time of the study. View
the study results here.

Worldwide, the market for cervical cancer screening and diagnostics, as
currently practiced using cytology (Pap test) for primary screening, is
estimated at $6 billion and is projected to grow to almost $9 billion by
2020. Worldwide there are about 2.6 billion women aged 15 years and
older who are at risk of developing cervical cancer.

About LuViva^® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva^®
Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial,
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use in the U.S. LuViva, the wave logo and “Early
detection, better outcomes” are registered trademarks owned by Guided
Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the sufficiency of capital raised in our prior financings and
our ability to realize their expected benefits, the uncertainty of
future capital to develop products or continue as a going concern, the
uncertainty of regulatory approval of products, and the dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2014
and subsequent filings.

Contacts

IRTH Communications
Robert Haag, 866-976-4784
Managing Partner
gthp@irthcommunications.com
or
Guided
Therapeutics
Bill Wells, 770-242-8723